已收录 272983 条政策
 政策提纲
  • 暂无提纲
Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus
[摘要] Background: Pulmonary arterial hypertension (PAH) is a recognised complication of SLE. The risk of developing PAH in SLE may be increased in a subset of patients with antiphospholipid antibodies. Aims: To estimate the point prevalence of PAH, to evaluate screening tests and to identify risk factors for PAH in a large cohort of SLE patients Methods: A prospective cross-sectional study of 288 patients with SLE using resting transthoracic echocardiography to estimate the systolic pulmonary artery pressures (sPAP) and to assess cardiac morphology and function. We assessed potential risk factors such as the presence of lung disease, autoantibodies and anti-phospholipid syndrome (APS). We evaluated screening tests such as pulmonary function tests, six minute walk test and biomarkers. Results: Twelve out of 283 patients had PAH with sPAP >30 mm Hg (range 31-59 mmHg). Only 3 patients had sPAP >40 mm Hg. The only significant risk factor for PAH was lupus anticoagulant (p=0.005). Conclusion: The point prevalence of PAH was 4.2% in our cohort of patients with SLE. The significant association of lupus anticoagulant and presence of APS in PAH cases suggests that thrombosis may play an important role in the development of PAH with SLE patients.
[发布日期]  [发布机构] University:University of Birmingham;Department:School of Immunity and Infection
[效力级别]  [学科分类] 
[关键词] R Medicine;RC Internal medicine [时效性] 
   浏览次数:3      统一登录查看全文      激活码登录查看全文